Pfizer still looks cheap, Barron's says

theflyonthewall.com

Even after Pfizer reported better than expected earnings and with a 3.1% yield the company still looks cheap. Share buybacks and new drug prospects show that the company has the cash and pipeline to drive the stock higher, Barron's contends in its Barron's Take column.

View Comments (0)